Jung Sung-hoon | Department Of Materials Science And Engineering Korean Advanced Institute Of Science And Technology
スポンサーリンク
概要
- 同名の論文著者
- Department Of Materials Science And Engineering Korean Advanced Institute Of Science And Technologyの論文著者
関連著者
-
Jung Sung-hoon
Department Of Materials Science And Engineering Korean Advanced Institute Of Science And Technology
-
Kim Hyeoung-joon
Department Of Hematology/oncology Chonnam National University Hwasun Hospital
-
Yang Deok-hwan
Department Of Hematology-oncology Chonnam National University Hwasun Hospital
-
LEE Je-Jung
Department of Hematology-Oncology, Chonnam National University Hwasun Hospital
-
KIM Yeo-Kyeoung
Department of Hematology-Oncology, Chonnam National University Hwasun Hospital
-
AHN Jae-Sook
Department of Hematology-Oncology, Chonnam National University Hwasun Hospital
-
Ahn Jae-sook
Department Of Hematology/oncology Chonnam National University Hwasun Hospital
-
Lee Je-jung
Department Of Hematology/oncology Chonnam National University Hwasun Hospital
-
Kim Yeo-kyeoung
Department Of Hematology/oncology Chonnam National University Hwasun Hospital
-
Kang Sang-won
Department Of Information And Communication Engineering Korea University
-
Kang Seung-Ji
Department of Internal Medicine, Chonnam National University Medical School
-
KIM Mi-Young
Department of Food and Nutrition, Chung-Ang University
-
KIM Mi-Young
Department of Hematology-Oncology, Chonnam National University Hwasun Hospital
-
PARK Hyungchul
Department of Hematology-Oncology, Chonnam National University Hwasun Hospital
-
BAE Soo-Young
Department of Hematology-Oncology, Chonnam National University Hwasun Hospital
-
KIM Hyeoung-Joon
Department of Hematology-Oncology, Chonnam National University Hwasun Hospital
著作論文
- Formation of TiO2 Thin Films using NH3 as Catalyst by Metalorganic Chemical Vapor Deposition
- Efficacy of stem cell mobilization in patients with newly diagnosed multiple myeloma after a CTD (cyclophosphamide, thalidomide, and dexamethasone) regimen
- Lymphocytopenia is associated with an increased risk of severe infections in patients with multiple myeloma treated with bortezomib-based regimens